Centessa Pharmaceuticals Plc ADR (CNTA) Stock Price, Quote & News

Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive...

Industry: Biotechnology

Sector: Healthcare

Website: centessa.com

Address:

1 Ashley Road, 3rd Floor, Altrincham, United Kingdom

TrendEdgeLogan Nov. 13 at 10:20 PM

I can still $SPOT several reasons that you $CNTA call $ONC 'le $INTA the $ASND 'ing seasonal tailwinds

0 · Reply

JarvisFlow Nov. 13 at 3:45 PM

Wells Fargo has adjusted their stance on Centessa Pharmaceuticals ( $CNTA ), setting the rating to Overweight with a target price of 30 → 35.

0 · Reply

Goldenpoint9 Nov. 13 at 2:06 PM

$CNTA

0 · Reply

theflynews Nov. 12 at 9:25 PM

What You Missed On Wall Street On Wednesday - $CNTA - https://thefly.com/permalinks/entry.php/CNTAid4238436?1762982548C38

0 · Reply

RunnerSignals Nov. 12 at 9:23 PM

Market Warriors on the Move! $CNTA $TRX.X $ERAS $RANI $CHGG started down but closed strong

0 · Reply

notreload_ai Nov. 12 at 8:33 PM

Morgan Stanley says Centessa’s ORX750 outperforms $ALKS drug, keeping an Overweight rating and $27 target on $CNTA.

0 · Reply

Quantumup Nov. 12 at 5:58 PM

TD Cowen $ALKS reiterated Buy; $40 PT $CNTA $TAK $ADVL Here's what TD Cowen had to say in its note:

0 · Reply

Quantumup Nov. 12 at 4:01 PM

Stifel reiterated $ALKS Buy/$42 $CNTA $TAK $AVDL Stifel said: ALKS disclosed this morning that alixorexton met the study's dual primary endpoints on MWT and ESS, with the 18mg dose hitting stat-sig on both, while the 14mg dose only hit on MWT. The p-values were close though, and on MWT specifically, the effect-sizes were lower than what some on the Street were expecting (~7pt PBO-adjusted from baseline in high-dose). ALKS attributed the results specifically on MWT -- which showed a lack of clear dose-response and ceiling effect on efficacy -- to more variable response at later intra-day assessments (6, 8hrs) and greater patient heterogeneity in NT2. As such, ALKS will be exploring BID and higher doses in the ph3, the latter being supported by a favorable disclosure on safety. As we see it, this still looks like a viable commercial product in NT2 where the bar is lower than much of the Street realizes-a 95% roll-over into the OLE corroborates this view.

0 · Reply

Quantumup Nov. 12 at 3:18 PM

Truist reiterated $ALKS Buy-$50, and said 'We Are Buyers of Today's Weakness,' after ALKS reported the much anticipated Vibrance-2 topline evaluating alixorexton in NT-2. $CNTA $TAK $AVDL Truist in its note said:

0 · Reply

_www_larval_com_ Nov. 12 at 2:42 PM

$BGLC 5%[-10%] $LFS -5%[-31%] $CRMD 5%[6%] $CNTA 5%[10%] $UPXI -5%[5%] most notable movement within the first minutes of trading.

0 · Reply

Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares

Nov 11, 2025, 4:00 PM EST - 3 days ago

Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares

Nov 7, 2025, 8:00 AM EST - 7 days ago

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Nov 5, 2025, 7:00 AM EST - 9 days ago

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program

Sep 3, 2025, 7:00 AM EDT - 2 months ago

Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 12, 2025, 7:00 AM EDT - 3 months ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025

Jul 4, 2025, 3:00 AM EDT - 4 months ago

Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa's Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist

Jun 16, 2025, 9:00 AM EDT - 5 months ago

Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year

May 14, 2025, 7:00 AM EDT - 6 months ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025

Mar 24, 2025, 7:00 AM EDT - 8 months ago

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

Mar 6, 2025, 4:14 PM EST - 9 months ago

Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting

Jan 8, 2025, 7:05 AM EST - 11 months ago

Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer

Dec 26, 2024, 12:31 PM EST - 11 months ago

Centessa: Shift In Focus With ORX750 Development Continues To Pay Off

Nov 12, 2024, 7:00 AM EST - 1 year ago

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Sep 26, 2024, 6:00 AM EDT - 1 year ago

Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Sep 12, 2024, 10:34 PM EDT - 1 year ago

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Sep 11, 2024, 4:04 PM EDT - 1 year ago

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Sep 11, 2024, 6:52 AM EDT - 1 year ago

Nxera Pharma's Partner Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Sep 10, 2024, 7:00 AM EDT - 1 year ago

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Aug 21, 2024, 8:00 AM EDT - 1 year ago

Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

Jun 10, 2024, 7:00 AM EDT - 1 year ago

Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer

May 13, 2024, 4:10 PM EDT - 1 year ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024

Apr 24, 2024, 2:20 PM EDT - 1 year ago

Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point

Apr 23, 2024, 9:36 PM EDT - 1 year ago

Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares

Apr 23, 2024, 4:17 PM EDT - 1 year ago

Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares

Apr 22, 2024, 7:00 AM EDT - 1 year ago

Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024

Mar 28, 2024, 4:28 PM EDT - 1 year ago

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023

Feb 9, 2024, 7:00 AM EST - 1 year ago

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and

Feb 5, 2024, 1:48 PM EST - 1 year ago

Centessa Pharmaceuticals: Clinical Advances And Unique Business Model Highlight Growth Potential

Dec 13, 2023, 8:00 AM EST - 2 years ago

Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference

Dec 10, 2023, 12:05 PM EST - 2 years ago

Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia

Nov 13, 2023, 4:05 PM EST - 2 years ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023

Nov 2, 2023, 9:09 AM EDT - 2 years ago

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting

Oct 31, 2023, 8:00 AM EDT - 2 years ago

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors

Oct 25, 2023, 8:00 AM EDT - 2 years ago

Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750's Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders

Sep 14, 2023, 5:31 AM EDT - 2 years ago

Centessa Pharmaceuticals: A Diversified Bet In Underserved Markets

Aug 23, 2023, 5:08 PM EDT - 2 years ago

Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress

Aug 17, 2023, 11:58 AM EDT - 2 years ago

Centessa Pharmaceuticals: Pipeline Progresses As PRESent-2 Initiated

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023

Jul 10, 2023, 8:00 AM EDT - 2 years ago

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors

May 22, 2023, 7:00 AM EDT - 2 years ago

Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B

May 12, 2023, 7:00 AM EDT - 2 years ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023

Mar 30, 2023, 7:00 AM EDT - 2 years ago

Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022

Mar 23, 2023, 4:30 PM EDT - 2 years ago

Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director

CLVT

Mar 1, 2023, 8:00 AM EST - 2 years ago

Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines

Feb 6, 2023, 8:00 AM EST - 3 years ago

Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

Feb 2, 2023, 8:00 AM EST - 3 years ago

Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference

Jan 26, 2023, 9:08 AM EST - 3 years ago

Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors

TrendEdgeLogan Nov. 13 at 10:20 PM

I can still $SPOT several reasons that you $CNTA call $ONC 'le $INTA the $ASND 'ing seasonal tailwinds

0 · Reply

JarvisFlow Nov. 13 at 3:45 PM

Wells Fargo has adjusted their stance on Centessa Pharmaceuticals ( $CNTA ), setting the rating to Overweight with a target price of 30 → 35.

0 · Reply

Goldenpoint9 Nov. 13 at 2:06 PM

$CNTA

0 · Reply

theflynews Nov. 12 at 9:25 PM

What You Missed On Wall Street On Wednesday - $CNTA - https://thefly.com/permalinks/entry.php/CNTAid4238436?1762982548C38

0 · Reply

RunnerSignals Nov. 12 at 9:23 PM

Market Warriors on the Move! $CNTA $TRX.X $ERAS $RANI $CHGG started down but closed strong

0 · Reply

notreload_ai Nov. 12 at 8:33 PM

Morgan Stanley says Centessa’s ORX750 outperforms $ALKS drug, keeping an Overweight rating and $27 target on $CNTA.

0 · Reply

Quantumup Nov. 12 at 5:58 PM

TD Cowen $ALKS reiterated Buy; $40 PT $CNTA $TAK $ADVL Here's what TD Cowen had to say in its note:

0 · Reply

Quantumup Nov. 12 at 4:01 PM

0 · Reply

Quantumup Nov. 12 at 3:18 PM

0 · Reply

_www_larval_com_ Nov. 12 at 2:42 PM

$BGLC 5%[-10%] $LFS -5%[-31%] $CRMD 5%[6%] $CNTA 5%[10%] $UPXI -5%[5%] most notable movement within the first minutes of trading.

0 · Reply

TrendEdgeLogan Nov. 12 at 2:41 PM

$CNTA Wild ride this one has been, $40 🧲

0 · Reply

DonCorleone77 Nov. 12 at 11:33 AM

$CNTA Centessa 11.63M share Spot Secondary priced at $21.50

0 · Reply

Profitrip Nov. 12 at 8:56 AM

$CNTA prices $250M offering at $21.5 per ADS / today $ELDN launches proposed public offering of common stock and pre-funded warrants / yesterday $IONS announces proposed convertible offering to refinance 2026 convertible notes / yesterday $BHVN launches $150 million proposed public offering / yesterday $SLRX Salarius stock slides after pricing $7M offering / yesterday

0 · Reply

Quantumup Nov. 11 at 12:31 PM

Truist🏁 $ALKS Buy/$50 $TAK $AVDL $CNTA Truist in its initiation report said: ALKS is a profitable biopharma with base business+cash worth ~$29/sh setting a high floor heading into Ph2 Vibrance-2 data in narcolepsy type 2 (NT2). Positive Vibrance-1 in NT1 reported in Sept de-risks imminent NT2 readout. NT1 alone is worth $8/sh in our SOTP valuation. NT2 and IH contribute $8/sh and $5/sh, respectively. ALKS is doubling down in sleep space with the acquisition of Avadel, a strategic move that gives ALKS first-mover advantage over Takeda. Current leading narcolepsy drugs are only at ~10% penetration generating ~$3B in sales. Orexin agonists, including ALKS' alixorexton, are poised to become 1st line therapies and expand mkt. Initiate BUY & $50 PT.

0 · Reply

JarvisFlow Nov. 7 at 6:49 PM

Wells Fargo updates rating for Centessa Pharmaceuticals ( $CNTA ) to Overweight, target set at 31 → 30.

0 · Reply

_www_larval_com_ Nov. 5 at 5:17 PM

$CNTA has reverted 3% higher to -8% (~6Mv) a moment ago, 11/21 options, follow for more volatility.

0 · Reply

d_risk Nov. 5 at 4:29 PM

$CNTA - Centessa Pharmaceuticals plc American Depositary Shares - 10Q - Updated Risk Factors Centessa’s updated risk factors spotlight challenges in sourcing and developing high-conviction drug candidates, fierce competition, costly deals, and pipeline risks tied to its asset-centric model. New and expanded risks include high drug development failure rates, clinical trial delays, regulatory hurdles (including rare disease and orphan drug complexities), heavy reliance on third parties for manufacturing and IP, extensive financing needs, and operational strains from limited resources and a small, dispersed team. Integration and execution risks from acquisitions, IP litigation threats, and commercialization hurdles—especially lacking sales infrastructure—are also emphasized. #Pharmaceuticals #IPLitigation #ClinicalTrials #RegulatoryChallenges #DrugDevelopmentRisks 🟢 Added 🟠 Removed https://d-risk.ai/CNTA/10-Q/2025-11-05

0 · Reply

notreload_ai Nov. 5 at 3:30 PM

$ALKS , $CNTA ... Centessa has great sleep drug data, easing daytime sleepiness. Alkermes stock jumped 7% as its competing drug is still strong. https://notreload.xyz/orexin-drug-race-centessa-shows-promise-alkermes-stands-strong/

0 · Reply

_www_larval_com_ Nov. 5 at 2:37 PM

$RPD -7%[-20%] $ALAB -7%[-2%] $CNTA 7%[-21%] $CYCU -7%[3%] $SLDP 6%[17%] most notable movement within the first minutes of trading.

0 · Reply

Quantumup Nov. 5 at 2:09 PM

Truist reiterated $CNTA Buy-$30, and said, CNTA shared the highly anticipated preliminary Ph 2a data with ORX750 in narcolepsy type 1 & 2 (NT1/NT2) and idiopathic hypersomnia (IH) this morning. $ALKS $TAK $AXSM Truist added, The results were disclosed in their 3Q25 earnings press release, and we connected with the company for additional clarity. Bottom-line: While the lack of detailed metrics limits direct comparisons to other OX2R agonist programs (Alkermes [ALKS, NR] and Takeda [TAK, NR]), the data appear to support the thesis that ORX750 could offer a best-in-class profile. Importantly, the results are validating of the approach in NT2 and IH. Based on these encouraging results, CNTA plans to initiate pivotal studies in 1Q26.

0 · Reply

Quantumup Nov. 5 at 2:02 PM

Stifel reiterated $ALKS Buy/$42: $CNTA $TAK We expect ALKS shares to trade higher today on some relief that the initial clinical disclosure from CNTA's orexin program does not look superior to what we've seen from ALKS2680. The fear/overhang on ALKS was that CNTA could have a much superior profile (we always viewed this as theoretical); that said, the NT1 efficacy disclosure (while it lacks some granularity) does not point to better efficacy. Conversely, CNTA also showed some positive data in NT2/IH -- which we see as validating for the class -- but again the effect is not out of this world, and for ALKS it lays out what we see as a realistic bar. Ultimately, we think orexins could be a significant blockbuster class and there is room for many players-ALKS, CNTA (Not covered) and Takeda (Not covered) included. But again, the important context here is that for ALKS, there were concerns that CNTA could be clearly superior, which we don't see.

0 · Reply

Quantumup Oct. 28 at 10:41 AM

Stephens🏁 $CNTA OW-$35: Anyone, Anyone... Anyone Heard Of Orexins; Initiating OW/Vol. We are initiating coverage of Centessa Pharmaceuticals Plc (NASDAQ: CNTA) with an Overweight(Volatile) rating and $35.00 price target. Lead asset ORX750, an orexin agonist, has demonstrated significant and dose-dependent improvements in mean sleep latency on the Maintenance of Wakefulness Test (MWT) which could have therapeutic benefits to narcolepsy (Type 1 and Type 2) and idiopathic hypersomnia (IH) patients. ORX750 is a novel, investigational orexin 2 receptor, OX2R, agonist in development for the treatment of NT1, NT2, and IH. Orexin is a key signaling neuropeptide triggering a cascade of neurotransmitter release. Produced in the hypothalamus, orexin plays an important role in promoting and stabilizing sleep. Other promising agents in development are: ORX142 and ORX489 in Phase 1 and IND-enabling studies for neurological & neurodegenerative disorders and neuropsychiatric disorders, respectively. $ALKS

0 · Reply

Market Cap	3.58B
Revenue (ttm)	0.00
Net Income (ttm)	-235.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.32

Volume	3,530,600
Avg Vol	1,511,768
Day's Range	N/A - N/A
Shares Out	133.91M
Stochastic %K	88%
Beta	1.56
Analysts	Strong Sell
Price Target	$33.92